Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Divalproex Sodium 500 mg Extended Release Tablets Under Fasting Conditions

This study has been completed.
Sponsor:
Information provided by:
Teva Pharmaceuticals USA
ClinicalTrials.gov Identifier:
NCT00974441
First received: September 9, 2009
Last updated: NA
Last verified: September 2009
History: No changes posted

September 9, 2009
September 9, 2009
August 2006
September 2006   (final data collection date for primary outcome measure)
  • Cmax - Maximum Observed Concentration [ Time Frame: Blood samples collected over 72 hour period ] [ Designated as safety issue: No ]
  • AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated) [ Time Frame: Blood samples collected over 72 hour period ] [ Designated as safety issue: No ]
  • AUC0-t - Area under the concentration-time curve from time zero to time of last quantifiable concentration (per participant) [ Time Frame: Blood samples collected over 72 hour period ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Divalproex Sodium 500 mg Extended Release Tablets Under Fasting Conditions
A Relative Bioavailability Study of 500 mg Divalproex Sodium Extended Release Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 500 mg Divalproex Sodium (equivalent to 500 mg Valproic Acid) Extended Release Tablets with that of Depakote® ER Tablets following a single oral dose (1 x 500 mg tablet) in healthy adult subjects administered under fasting conditions.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Healthy
  • Drug: Divalproex Sodium
    500 mg Extended Release Tablet
  • Drug: Depakote®
    500 mg Extended Release Tablet
  • Experimental: Divalproex Sodium
    500 mg Extended Release Tablet
    Intervention: Drug: Divalproex Sodium
  • Active Comparator: Depakote®
    500 mg Extended Release Tablet
    Intervention: Drug: Depakote®
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
48
September 2006
September 2006   (final data collection date for primary outcome measure)

Inclusion Criteria

  • Subjects who have completed the screening process within 28 days prior to Period 1 dosing
  • Subjects who are healthy adult men and women 18 years of age or older at the time of dosing.
  • Subjects who have a body mass index (BMI) between 19-30 kg/m2, inclusive, and weigh at least 110 lbs.
  • Subjects who are healthy as documented by the medical history, physical examination (including bur may not be limited to and evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous systems), vital sign assessments, 12-lead electrocardiogram (ECG), clinical laboratory assessments, and by general observations. Any abnormalities/deviations from the normal range that might be considered clinically relevant by the study physician and investigator will be evaluated for individual cases, documented in study files and agreed upon by both the study physician and investigator prior to enrolling the subject in this study and for continued enrollment.
  • Female subjects of postmenopausal (no menses) status for at least 1 year and has a serum FSH level greater than or equal to 30 mIU/mL or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy).

Exclusion Criteria

  • Subjects who report receiving any investigational drug within 30 days prior to Period 1 dosing.
  • Subjects who report any presence or history of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease as determined by the clinical investigator(s).
  • Subjects whose clinical laboratory test values outside the accepted reference range and when confirmed on re-examination is deemed to be clinically significant.
  • Subjects who demonstrate a reactive screen for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody.
  • Subjects who report a history or allergic response(s) to divalproex or related drugs.
  • Subjects who report the use of any systemic prescription medication in the 14 days prior to Period 1 dosing.
  • Subjects who report the use of any drug known to induce or inhibit hepatic drug metabolism in the 28 days prior to Period 1 dosing.
  • Subjects who report a history of clinically significant allergies including drug allergies.
  • Subjects who report a clinically significant illness during the 4 weeks prior to Period 1 dosing (as determined by the clinical investigators).
  • Subjects who report a history of drug or alcohol addiction or abuse within the past year.
  • Subjects who demonstrate a positive drug abuse screen for this study prior to Period 1 administration.
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00974441
R06-0441
No
Not Provided
Teva Pharmaceuticals USA
Not Provided
Principal Investigator: James D Carlson, Pharm. D PRACS Institute, Ltd.
Teva Pharmaceuticals USA
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP